Stock Ratings / Technology / HCAT / dividends

SANG (60) DOYU (36) DSC (62) PODC (55) ⌘ Pro Terminal →

Health Catalyst Inc (HCAT) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.79 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.78

Health Catalyst Inc (HCAT) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $134.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.78 (-0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCAT)Realized 20D OHLCV Swing Band: ±11.2%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY HCAT SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (31% of score)

FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 46.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.77-2.3% Next Q

Q2 (-2Q)

Grade E$1.73-2.3% Next Q

Q3 (-1Q)

Grade E$1.69+5.9% Next Q

Current

Grade D-$1.79-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HCAT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HCAT currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Technology with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.72) and Max Pain ($1.88) forces dealer call-delta covering toward $3.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCAT• $4.8M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HCAT Beats Next Quarterly Revenue & EPS Consensus + Hyperscaler AI CapEx Holds Record Pace”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCAT)

✓Walkthrough of HCAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.20%▲ ASCENDING CHANNEL

2026-10-30O $1.79H $1.84L $1.66C $1.79VOL 345.0K

RES: $2.86SUP: $1.57SMA50: $1.72SMA200: $1.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCAT Butterfly Map → + Track HCAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCAT)

Technology Rank #622 of 714 ⚔️ SANG vs HCAT Full Matrix →

1. Head-to-Head Technology Peer Comparison (HCAT vs. SANG, DOYU, DSC, PODC)

Industry: Computer Software: Programming Data Processing (72 Tracked Issuers)

Across 714 tracked Technology securities in the Roarable RQD universe, Health Catalyst Inc (HCAT) ranks #622 by composite RQD confidence (35/100, grade D-) and #505 by equity capitalization ($134.7M). Within this direct 5-issuer industry benchmark cohort, HCAT leads on earnings valuation at N/A trailing P/E, while DOYU leads on capital efficiency and profitability with 1.6% ROIC and 12.8% gross margin. DSC currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with HCAT at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCAT ACTIVE Health Catalyst Inc	D-	35/100	—	—	-35.0%	-0.56%	$134.7M	Benchmark Subject
SANG Sangoma Technologies Corporation	C-	60/100	—	—	—	+1.07%	$157.9M	/sang-vs-hcat →
DOYU DouYu International Holdings Limited ADS	D-	36/100	—	12.8%	1.6%	-0.55%	$110.2M	/doyu-vs-hcat →
DSC DSC Holdings Ltd.	C	62/100	—	—	—	+4.53%	$184.8M	/dsc-vs-hcat →
PODC PodcastOne Inc.	D+	55/100	—	—	-16.9%	+5.71%	$78.4M	/podc-vs-hcat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636422

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Health Catalyst Inc (HCAT) reported GAAP revenue of $311.1M (+1.5% vs. FY2024 revenue of $306.6M , and +5.1% cumulative change since FY2023) , GAAP net income of -$178.0M, operating cash flow of $731.0K, and free cash flow of -$237.0K (-101.8% YoY). On the balance sheet, HCAT closed FY2025 with $502.6M in total assets against $151.6M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$311.1M	-$178.0M	$731.0K	-$237.0K	$502.6M	$151.6M
FY2024 (FY)	2024-12-31	$306.6M	-$69.5M	$14.6M	$12.9M	$858.9M	$151.2M
FY2023 (FY)	2023-12-31	$295.9M	-$118.1M	-$33.1M	-$33.1M	—	—

3. HCAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Health Catalyst Inc (NASDAQ: HCAT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.79 (-0.56% 1D, market cap $134.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 714 tracked Technology issuers, HCAT ranks #622 in composite RQD confidence.

How does HCAT compare to SANG and DOYU in the Technology sector?

Within the Technology sector (Computer Software: Programming Data Processing), HCAT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANG (Sangoma Technologies Corporation) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $157.9M) and DOYU (DouYu International Holdings Limited ADS) posts a D- grade (36/100 RQD, P/E N/A, ROIC 1.6%, cap $110.2M). Among the 5-stock peer group, HCAT leads on earnings multiple (N/A) while DOYU leads on capital efficiency (1.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCAT?

Per HCAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636422), Health Catalyst Inc generated $311.1M in revenue (+1.5% YoY), -$178.0M in net income, and -$237.0K in free cash flow against $502.6M in total assets and $151.6M in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCAT trading relative to its 50-day, 200-day, and 52-week technical levels?

HCAT last traded at $1.79 (-0.56% on volume of 282,318 shares), positioning the stock +4.07% above its 50-day simple moving average ($1.72) and +4.07% above its 200-day simple moving average ($1.72). Across its 52-week range of $0.96 to $3.36, HCAT sits at the 34.6% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($1.59 to $1.99).

HCAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does HCAT pay a dividend and is it safe?

Health Catalyst Inc (HCAT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: HCAT RQD Cockpit HCAT 12M Forecast HCAT Earnings & Move HCAT Dividends & DRIP HCAT Insiders & 13F HCAT Whale Options HCAT Profit Sankey HCAT News & Why